Cummings Jeffrey, Morstorf Travis, Lee Garam
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Touro University Nevada, Henderson, NV, USA.
Alzheimers Dement (N Y). 2016 Aug 17;2(4):222-232. doi: 10.1016/j.trci.2016.07.001. eCollection 2016 Nov.
Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed.
We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD.
There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying treatments (DMTs). Most DMTs address amyloid-related targets (76%). There are 45 agents in phase II being assessed in 52 clinical trials. Phase II trials include 30 DMTs, with 26 small molecules and 4 immunotherapies. There are 24 agents in the first phase of AD drug development.
Amyloid is the principal target of late-stage development programs. There are relatively few agents in clinical trials for AD suggesting a need to amplify the drug discovery ecosystem.
阿尔茨海默病（AD）的发病率正在上升，迫切需要新的治疗方法。
我们评估了clinicaltrials.gov（于2016年4月1日访问），以确定治疗AD的I期、II期和III期试验的数量及特征。
目前在AD药物开发的III期有36项试验中的24种药物。这24种药物中有7种是有症状的认知增强化合物，17种是疾病修饰治疗（DMTs）。大多数DMTs针对与淀粉样蛋白相关的靶点（76%）。在II期有45种药物正在52项临床试验中进行评估。II期试验包括30种DMTs，其中有26种小分子药物和4种免疫疗法。在AD药物开发的第一阶段有24种药物。
淀粉样蛋白是后期开发项目的主要靶点。AD临床试验中的药物相对较少，这表明需要扩大药物发现生态系统。
